Trial reportEuropean journal of clinical pharmacology2016
Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
Trial report in European journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Medicinal Plants for Major Depressive Disorder.Brain sciences · 2026Review
- Artificial Intelligence Models and Tools for the Assessment of Drug-Herb Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Adaptogens in Long-Lasting Brain Fatigue: An Insight from Systems Biology and Network Pharmacology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- State-of-the-Art Review on Botanical Hybrid Preparations in Phytomedicine and Phytotherapy Research: Background and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Herb-drug Interactions in Neuropsychiatric Pharmacotherapy - A Review of Clinically Relevant Findings.Current neuropharmacology · 2022Review
- A Practical Perspective on the Use of Botanicals During the COVID-19 Pandemic: From Proven to Potential Interactions.Journal of medicinal food · 2022Review
- Quality Evaluation of Randomized Controlled Trials ofEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.Medicinal research reviews · 2021Review
- Multifaceted Factors Causing Conflicting Outcomes in Herb-Drug Interactions.Pharmaceutics · 2020Review
- Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa.Pharmacology research & perspectives · 2020Article
- PharmActa: Empowering Patients to Avoid Clinical Significant Drug⁻Herb Interactions.Medicines (Basel, Switzerland) · 2019Article
- Assessing the Quality and Potential Efficacy of Commercial Extracts ofFrontiers in pharmacology · 2018Article
- Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product.Pharmacology research & perspectives · 2017Article
- Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.Evidence-based complementary and alternative medicine : eCAM · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present study was to evaluate the effect of the herbal drug Rhodiola rosea on the activity of the cytochrome P-450 (CYP) enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in humans.
methodsIn a randomized cross-over study, 13 healthy volunteers were given a cocktail with single doses of the CYP substrates caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4) with and without 14 days of pretreatment with a commercially available R. rosea product (Arctic Root, produced by the Swedish Herbal Institute). Four hours after intake of the drug cocktail, a blood sample was obtained, the serum concentrations of the drugs and their metabolites were analyzed, and the metabolic ratios were calculated as a measure of CYP enzyme activity.
resultsA statistically significant 21% decrease in the EXP-3174/losartan ratio was found after pretreatment with R. rosea (p = 0.023), indicating a reduced CYP2C9 metabolic activity. The effect was more pronounced in CYP2C9 extensive metabolizers than in CYP2C9 intermediate and poor metabolizers. For the other CYP enzymes tested, no significant effects were observed.
conclusionsThis study indicates that R. rosea inhibits the metabolic capacity of CYP2C9 in humans. Although the effect is modest, it might be clinically relevant during treatment with CYP2C9 substrates with a narrow therapeutic index, such as phenytoin and warfarin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.